ABSTRACT
Huosu Yangwei (HSYW) Formula is a traditioanl Chinese herbal medicine that has been extensively used to treat chronic atrophic gastritis, precancerous lesions of gastric cancer and advanced gastric cancer. However, the effective compounds of HSYW and its related anti-tumor mechanisms are not completely understood. In the current study, 160 ingredients of HSYW were identified and 64 effective compounds were screened by the ADMET evaluation. Furthermore, 64 effective compounds and 2579 potential targets were mapped based on public databases. Animal experiments demonstrated that HSYW significantly inhibited tumor growth in vivo. Transcriptional profiles revealed that 81 mRNAs were differentially expressed in HSYW-treated N87-bearing Balb/c mice. Network pharmacology and PPI network showed that 12 core genes acted as potential markers to evaluate the curative effects of HSYW. Bioinformatics and qRT-PCR results suggested that HSYW might regulate the mRNA expression of DNAJB4, CALD, AKR1C1, CST1, CASP1, PREX1, SOCS3 and PRDM1 against tumor growth in N87-bearing Balb/c mice.
Subject(s)
Animals , Mice , Biomarkers , China , Drugs, Chinese Herbal , Network Pharmacology , Stomach Neoplasms/geneticsABSTRACT
The relationship between sub-health and " pro-disease" in Chinese medicine was clarified through analyzing the background of sub-health coming forth and its connotation, as well as the multiple meaning of "pro-disease" in Chinese medicine. The authors offered, thereupon, their clews and methods for treatment of "pro-disease" and intervention on sub-health.